| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 01/06/2024 | 14:00 | PR Newswire (US) | Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting | NYSE:LLY | Eli Lilly and Co |
| 31/05/2024 | 20:32 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:LLY | Eli Lilly and Co |
| 30/05/2024 | 22:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:LLY | Eli Lilly and Co |
| 29/05/2024 | 12:00 | PR Newswire (US) | Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases | NYSE:LLY | Eli Lilly and Co |
| 28/05/2024 | 16:00 | PR Newswire (US) | Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference | NYSE:LLY | Eli Lilly and Co |
| 28/05/2024 | 13:37 | IH Market News | iPhone Sales Skyrocket in China, Nvidia Surges in Pre-Market Following xAI Fundraising, and More News | NYSE:LLY | Eli Lilly and Co |
| 24/05/2024 | 15:30 | PR Newswire (US) | Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines | NYSE:LLY | Eli Lilly and Co |
| 23/05/2024 | 23:00 | PR Newswire (US) | Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NYSE:LLY | Eli Lilly and Co |
| 21/05/2024 | 14:00 | PR Newswire (US) | More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure | NYSE:LLY | Eli Lilly and Co |
| 21/05/2024 | 13:18 | IH Market News | CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News | NYSE:LLY | Eli Lilly and Co |
| 16/05/2024 | 12:45 | PR Newswire (US) | With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin | NYSE:LLY | Eli Lilly and Co |
| 15/05/2024 | 14:00 | PR Newswire (US) | Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer | NYSE:LLY | Eli Lilly and Co |
| 09/05/2024 | 22:34 | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:LLY | Eli Lilly and Co |
| 06/05/2024 | 17:32 | PR Newswire (US) | Lilly Declares Second-Quarter 2024 Dividend | NYSE:LLY | Eli Lilly and Co |
| 30/04/2024 | 15:07 | IH Market News | Futures Pointing To Roughly Flat Open On Wall Street | NYSE:LLY | Eli Lilly and Co |
| 30/04/2024 | 13:59 | IH Market News | U.S. Index Futures Point to Mild Decline Ahead of Key Earnings and Fed Rate Decision | NYSE:LLY | Eli Lilly and Co |
| 30/04/2024 | 13:55 | IH Market News | HSBC’s High Profit & CEO Resignation, Santander’s 11% Profit Surge, and More in Earnings | NYSE:LLY | Eli Lilly and Co |
| 30/04/2024 | 12:45 | PR Newswire (US) | Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum | NYSE:LLY | Eli Lilly and Co |
| 17/04/2024 | 12:15 | PR Newswire (US) | Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity | NYSE:LLY | Eli Lilly and Co |
| 16/04/2024 | 16:00 | PR Newswire (US) | Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement | NYSE:LLY | Eli Lilly and Co |
| 03/04/2024 | 13:12 | IH Market News | Cal-Maine Surges on Strong Quarterly Performance, Taiwan Earthquake Disrupts Tech Supply Chain, and More | NYSE:LLY | Eli Lilly and Co |
| 10/03/2024 | 21:00 | PR Newswire (US) | More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study | NYSE:LLY | Eli Lilly and Co |
| 08/03/2024 | 12:45 | PR Newswire (US) | U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab | NYSE:LLY | Eli Lilly and Co |
| 07/03/2024 | 14:00 | PR Newswire (US) | Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care | NYSE:LLY | Eli Lilly and Co |
| 05/03/2024 | 23:00 | PR Newswire (US) | Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting | NYSE:LLY | Eli Lilly and Co |
| 20/02/2024 | 16:00 | PR Newswire (US) | Lilly to Participate in Cowen's 44th Annual Health Care Conference | NYSE:LLY | Eli Lilly and Co |
| 13/02/2024 | 23:04 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NYSE:LLY | Eli Lilly and Co |
| 09/02/2024 | 15:30 | PR Newswire (US) | Philip Johnson to Retire as Lilly Treasurer | NYSE:LLY | Eli Lilly and Co |
| 08/02/2024 | 22:51 | Edgar (US Regulatory) | Form 424B2 - Prospectus [Rule 424(b)(2)] | NYSE:LLY | Eli Lilly and Co |
| 07/02/2024 | 23:08 | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses | NYSE:LLY | Eli Lilly and Co |